Cellular immunotherapy in multiple myeloma

키워드

참고문헌 (72)

1. Sirohi B, "Multiple myeloma", Lancet, 363, pp.875~887 (2004)
2. Kyle RA, "Multiple myeloma", N Engl J Med, 351, pp.1860~1873 (2004)
3. Junshik Hong, "Recent advances in multiple myeloma: a Korean perspective", The Korean Journal of Internal Medicine, 31(5), pp.820~834 (2016), 대한내과학회[DOI]
4. Lonial S, "Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma", Br J Haematol, 145, pp.681~708 (2009)
5. Attal M, "The role of high-dose therapy with autologous stem cell support in the era of novel agents", Semin Hematol, 46, pp.127~132 (2009)
6. and their uses in immunotherapies, "Blood Cancer J", 2015, e306~
7. Leung W, "Immunotherapy in acute leukemia", Semin Hematol, 46, pp.89~99 (2009)
8. Guillerey C, "Immune responses in multiple myeloma : role of the natural immune surveillance and potential of immunotherapies", Cell Mol Life Sci, 73, pp.1569~1589 (2016)
9. Lim WA, "The principles of engineering immune cells to treat cancer", Cell, 168, pp.724~740 (2017)
10. Bensinger W, "Allo-SCT for multiple myeloma : a review of outcomes at a single transplant center", Bone Marrow Transplant, 47, pp.1312~1317 (2012)
11. Quach H, "Mechanism of action of immunomodulatory drugs(IMiDS)in multiple myeloma", Leukemia, 24, pp.22~32 (2010)
12. Vo MC, "Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model", Oncotarget, 8, pp.27252~27262 (2017)
13. Vo MC, "Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells", Oncotarget, 8, pp.46047~46056 (2017)
14. Al-Hujaily EM, "Development of novel immunotherapies for multiple myeloma", Int J Mol Sci, 17, pp.E1506~ (2016)
15. Rosenblatt J, "Targeting the PD-1", PD-L1 axis in multiple myeloma: a dream or a reality?, 2017, pp.129, 275~279
16. Jung SH, "Immunotherapy for the treatment of multiple myeloma", Crit Rev Oncol Hematol, 111, pp.87~93 (2017)
17. Kim YS, "A novel function of API5(apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells", Oncoimmunology, 7, pp.e1472187~ (2018)
18. Ratta M, "Dendritic cells are functionally defective in multiple myeloma : the role of interleukin-6", Blood, 100, pp.230~237 (2002)
19. Vo MC, "Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma", Exp Hematol, 46, pp.48~55 (2017)
20. Liso A, "Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma", Biol Blood Marrow Transplant, 6, pp.621~627 (2000)
21. Jung SH, "Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro", Exp Hematol, 42, pp.274~281 (2014)
22. Choi NR, "Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco", endoplasmic reticulum Ca(2+)transport ATPase 2 regulation, 2015, pp.17, 1421~1433
23. My-Dung Hoang, "Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic", 전남의대학술지, 51(1), pp.1~7 (2015), 의과학연구소
24. Hoang MD, "Branched polyethylenimine-superparamagnetic iron oxide nanoparticles(bPEI-SPIONs)improve the immunogenicity of tumor antigens and enhance Th1 polarization of dendritic cells", J Immunol Res, 2015, pp.706379~ (2015)
25. Cheol Yi Hong, "Sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2)reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells", Experimental and Molecular Medicine, 48, pp.1~9 (2016), 생화학분자생물학회
26. Lee HJ, "Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine", Methods Mol Biol, 1139, pp.17~26 (2014)
27. Vo MC, "Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity", Oncotarget, 6, pp.33781~33790 (2015)
28. Jung SH, "A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma", Oncotarget, 8, pp.41538~41548 (2017)
29. Neuber B, "Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma", J Immunol, 187, pp.1047~1056 (2011)
30. Nguyen-Pham TN, "Lenalidomide synergistically enhances the effect of dendritic cell vacci nation in a model of murine multiple myeloma", J Immunother, 38, pp.330~339 (2015)
31. Vo MC, "Synergistic antimyeloma activity of dendritic cells and pomalidomide in a murine myeloma model", Front Immunol, 9, pp.1798~ (2018)
32. Rosenblatt J, "PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell", myeloma fusion vaccine, 2011, pp.34, 409~418
33. Vo MC, "Lenalidomide and programmed death-1 blockade synergistically enhances the effects of dendritic cell vaccination in a model of murine myeloma", Front Immunol, 9, pp.1370~ (2018)
34. Kochenderfer JN, "Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors", Nat Rev Clin Oncol, 10, pp.267~276 (2013)
35. Ramos CA, "Clinical responses with T lymphocytes targeting malignancy-associated κlight chains", J Clin Invest, 126, pp.2588~2596 (2016)
36. Maude SL, "CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia", Blood, 125, pp.4017~4023 (2015)
37. Sadelain M, "The basic principles of chimeric antigen receptor design", Cancer Discov, 3, pp.388~398 (2013)
38. Zhao Z, "Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells", Cancer Cell, 28, pp.415~428 (2015)
39. "First-ever CAR T-cell therapy approved in U.S", Cancer Discov, 7, pp.OF1~ (2017)
40. Mikkilineni L, "Chimeric antigen receptor T-cell therapies for multiple myeloma", Blood, 130, pp.2594~2602 (2017)
41. Mackay CR, "Expression and modulation of CD44 variant isoforms in humans", J Cell Biol, 124, pp.71~82 (1994)
42. Kawamura T, "CD70 is selectively expressed on Th1 but not on Th2 cells and is required for Th1-type immune responses", J Invest Dermatol, 131, pp.1252~1261 (2011)
43. Van Acker HH, "CD56 in the immune system: more than a marker for cytotoxicity?", Front Immunol, 8, pp.892~ (2017)
44. Drent E, "A rational strategy for reducing on-target off-tumor effects of cd38-chimeric antigen receptors by affinity optimization", Mol Ther, 25, pp.1946~1958 (2017)
45. Harada H, "Phenotypic difference of normal plasma cells from mature myeloma cells", Blood, 81, pp.2658~2663 (1993)
46. Podar K, "Handbook of Cell Signaling", pp.2799~2809 (2010), Academic Press
47. Guo B, "CD138-directed adoptive immunotherapy of chimeric antigen receptor(CAR)-modified T cells for multiple myeloma", J Cell Immunother, 2, pp.28~35 (2016)
48. Garfall AL, "Anti-CD19CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma", JCI Insight, 3, pp.e120505~ (2018)
49. Matsui W, "Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance", Cancer Res, 68, pp.190~197 (2008)
50. Raje NS, "bb2121 Anti-BCMA CAR T-cell therapy in patients with relapsed", refractory multiple myeloma: updated results from a multicenter phase I study, 2018, pp.36(15 Suppl), 8007~
51. Cohen AD, "Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM)", Blood, 130(Suppl 1), pp.505~ (2017)
52. Smith EL, "Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector", Mol Ther, 26, pp.1447~1456 (2018)
53. Fan F, "Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory", relapsed multiple myeloma, 2017, pp.35(18 Suppl), LBA3001~
54. Yan L, "Combined infusion of CD19and Bcma-specific chimeric antigen receptor T cells for RRMM: initial safety and efficacy report from a clinical pilot study", Blood, 130(Suppl 1), pp.506~ (2017)
55. Ping Y, "T-cell receptor-engineered T cells for cancer treatment : current status and future directions", Protein Cell, 9, pp.254~266 (2018)
56. Kunert A, "TCR-engineered T cells meet new challenges to treat solid tumors : choice of antigen, T cell fitness, and sensitization of tumor milieu", Front Immunol, 4, pp.363~ (2013)
57. Debets R, "TCR-engineered T cells to treat tumors: seeing but not touching?", Semin Immunol, 28, pp.10~21 (2016)
58. Rapoport AP, "NYESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma", Nat Med, 21, pp.914~921 (2015)
59. Malhotra A, "NK cells : immune cross-talk and therapeutic implications", Immunotherapy, 3, pp.1143~1166 (2011)
60. Rezvani K, "The application of natural killer cell immunotherapy for the treatment of cancer", Front Immunol, 6, pp.578~ (2015)
61. Marcus A, "Recognition of tumors by the innate immune system and natural killer cells", Adv Immunol, 122, pp.91~128 (2014)
62. Tamura H, "Immunopathogenesis and immunotherapy of multiple myeloma", Int J Hematol, 107, pp.278~285 (2018)
63. Frohn C, "Anti-myeloma activity of natural killer lymphocytes", Br J Haematol, 119, pp.660~664 (2002)
64. Garg TK, "Highly activated and expanded natural killer cells for multiple myeloma immunotherapy", Haematologica, 97, pp.1348~1356 (2012)
65. Shah N, "Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity", PLoS One, 8, pp.e76781~ (2013)
66. Szmania S, "Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients", J Immunother, 38, pp.24~36 (2015)
67. Shah N, "Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma", Br J Haematol, 177, pp.457~466 (2017)
68. Leivas A, "Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma", Oncoimmunology, 5, pp.e1250051~ (2016)
69. Chu J, "CS1-specific chimeric antigen receptor(CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma", Leukemia, 28, pp.917~927 (2014)
70. Liu D, "Chimeric antigen receptor(CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV", Protein Cell, 8, pp.861~877 (2017)
71. Glienke W, "Advantages and applications of CAR-expressing natural killer cells", Front Pharmacol, 6, pp.21~ (2015)
72. von Strandmann EP, "A novel bispecific protein(ULBP2-BB4)targeting the NKG2D receptor on natural killer(NK)cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo", Blood, 107, pp.1955~1962 (2006)

관련 논문AI추천